Sphere Fluidics

Sphere Fluidics Launches Cyto-CellectPLUS to Accelerate Cell Line Development Workflows

Retrieved on:

星期二, 六月 4, 2024

Health, Medical Devices, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Transfer, Cell and molecular biology, Cell, FRET, Molecular biology, Cell engineering, Immortalised cell line, Immunoglobulin G, Synthetic biology, Sphere Fluidics, Sphere, Single-cell analysis

Expanding on Sphere Fluidics’ original Cyto-Cellect Human IgGκ Detection Kit, Cyto-CellectPLUS now detects both the IgG κ and λ light chains to support a broader range of projects.

Key Points:

Expanding on Sphere Fluidics’ original Cyto-Cellect Human IgGκ Detection Kit, Cyto-CellectPLUS now detects both the IgG κ and λ light chains to support a broader range of projects.
The assay is fully compatible with existing Cyto-Mine functionality, including single cell dispensing into 96-well and 384-well plates, allowing it to seamlessly integrate into customers’ existing cell line development workflows and conforms to relevant regulatory requirements by being animal-origin-free.
This accelerated throughput is already widely recognized across a variety of research areas, including antibody discovery, cell line development, cell engineering and synthetic biology.
This launch demonstrates ongoing innovation and expansion of our capabilities, in line with our plans to accelerate commercial roll out.

Sphere Fluidics Appoints Dale Levitzke as Chief Executive Officer

Retrieved on:

星期二, 四月 30, 2024

In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.

Key Points:

In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.
Throughout his career, Dale has focused on supporting early-stage and VC-backed pioneering tools companies and steering them towards global market success.
Dr. Frank F. Craig co-founded Sphere Fluidics, alongside Professor Chris Abell and Professor Wilhelm Huck, before becoming CEO in 2010.
Dale Levitzke, incoming CEO, Sphere Fluidics, added: “Sphere Fluidics’ picodroplet technology and microfluidics platforms are transforming single cell analysis and isolation capabilities, bringing new possibilities to biopharmaceutical research and development.

Sphere Fluidics Appoints Edward Rayner as Non-Executive Director

Retrieved on:

星期三, 四月 17, 2024

Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Single-cell analysis, University of Oxford, Management, Ed, Master of Science, Sphere Fluidics, AMP Capital, Drug development, Growth

Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Ed Rayner to its Board of Directors as a Non-Executive Director.

Key Points:

Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Ed Rayner to its Board of Directors as a Non-Executive Director.
He has an MA in Chemistry and MSc in Management from Oxford University, and is a Chartered Financial Analyst.
Dr. Frank F. Craig, CEO, Sphere Fluidics, commented: “We’re very pleased that Ed has joined the Sphere Fluidics Board.
His acumen will help us map out our growth plans, competitive positioning and a strong exit.”
Ed Rayner, Non-Executive Board Director, Sphere Fluidics, added: “I’m excited to join the Sphere Fluidics Board to support the Company as it accelerates its commercial roll out.

Sphere Fluidics’ Cyto-Mine System Selected by FairJourney Biologics to Advance Cell Line Development Workflows

Retrieved on:

星期二, 十月 3, 2023

Biotechnology, Pharmaceutical, Health, Medical Devices, Immortalised cell line, GLP, Sphere Fluidics, Therapy, Research, Sphere, Engineering, Drug discovery, Title 21 CFR Part 11, Knowledge, Cell engineering, FDA, Synthetic biology, Vaccine

FairJourney Biologics has adopted the platform as part of the launch for its latest cell line development services, to streamline and accelerate customer workflows.

Key Points:

FairJourney Biologics has adopted the platform as part of the launch for its latest cell line development services, to streamline and accelerate customer workflows.
FairJourney Biologics’ team of experts comprises an extensive knowledge of cellular biology, enabling them to tailor cell lines precisely to their partners' unique requirements.
Leveraging state-of-the-art technologies and meticulous quality control measures, FairJourney Biologics consistently delivers high-performing, stable cell lines that serve as the foundation for efficient antibody production and therapeutics development.
The integration of Sphere Fluidics’ Cyto-Mine platform into our cell line development workflows enables us to best cater to our partners’ needs, to provide high-quality, customized cell lines in a fraction of the time.”

Sphere Fluidics Updates Brand Identity to Align With Ambitious, Global Commercial Growth Strategy

Retrieved on:

星期二, 五月 23, 2023

Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Acceleration, Synthetic biology, Sphere Fluidics, Growth, EU, Identity, Metastasis, Cell encapsulation, Fine chemical, Management, Granta Park

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the introduction of new branding to align with its ambitious global commercial growth strategy.

Key Points:

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the introduction of new branding to align with its ambitious global commercial growth strategy.
The update has been introduced to better reflect the Company’s customer-centric approach and showcase its pioneering single cell discovery and analysis technology, following a period of significant growth and program success.
Sphere Fluidics’ range of novel cell encapsulation products for single cell analysis and isolation are aimed at easing customer workflows to accelerate scientific discovery.
Sphere Fluidics’ core focus is on working with scientists to solve throughput challenges.

Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors

Retrieved on:

星期二, 五月 2, 2023

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors.

Key Points:

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors.
With over 30 years in the healthcare industry, Ken brings extensive strategic advisory, M&A, underwriting and other transactional expertise.
Kenneth Hitchner, Chairman of Board of Directors, Sphere Fluidics, commented: “Sphere Fluidics is changing the face of cell line development.
This expertise will help us in our future plans for building business value and ultimately exiting via a Trade Sale or IPO.”
For more information about Sphere Fluidics, please visit: https://spherefluidics.com/

Sphere Fluidics Begins Work With Partners on 3DSecret Program to Investigate Mechanisms of Metastasis in Cancer

Retrieved on:

星期一, 四月 24, 2023

Coordinated by the International Iberian Nanotechnology Laboratory (INL), the consortium has been awarded €3.4M and aims to develop novel technologies to investigate the stochastic patterns behind metastasis at the single-cell level, to predict cancer evolution.

Key Points:

Coordinated by the International Iberian Nanotechnology Laboratory (INL), the consortium has been awarded €3.4M and aims to develop novel technologies to investigate the stochastic patterns behind metastasis at the single-cell level, to predict cancer evolution.
3DSecret brings together multidisciplinary experts in microfluidics, nanosensors, artificial intelligence (AI), cell genomics and transcriptomics from four European countries (Portugal, Spain, Italy and the United Kingdom).
As a consortium partner, Sphere Fluidics is providing its patented picodroplet technology to support development of an integrated microfluidic device, the 3DSecret-chip, for the reproducible and controlled formation of 3D spheroids from single cancer cells.
Funding was awarded to 3DSecret ( www.3dsecret.eu ) in October 2022 and the project will run to the end of 2026.

Sphere Fluidics Appoints Richard Hammond as Chief Technical Officer

Retrieved on:

星期二, 十二月 13, 2022

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Richard Hammond as Chief Technical Officer.

Key Points:

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Richard Hammond as Chief Technical Officer.
In his role as Chief Technical Officer, Richard will be responsible for driving innovation and growing Sphere Fluidics product range, including productizing several patented prototypes currently in development.
Richard Hammond, MA MEng, joins Sphere Fluidics with over 20 years experience in managing the development of cutting-edge commercial products for healthcare and life sciences.
Richard Hammond, CTO, Sphere Fluidics, commented: Sphere Fluidics has an excellent reputation for providing world-class products for single cell analysis, and Im delighted to take the opportunity to build on this further.

Sphere Fluidics Opens New Laboratory Facilities at Granta Park in Cambridgeshire, UK

Retrieved on:

星期二, 十月 25, 2022

Health, Stem Cells, Genetics, Research, Science, Biotechnology, Laboratory, Sphere Fluidics, Workforce, Sphere, Company, CEO, Environment, View, Granta Park

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Companys growth.

Key Points:

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Companys growth.
The new facilities accommodate recent hires to Sphere Fluidics commercial and leadership team, as well as preparing for further recruitment by the end of the year.
Custom designed and renovated by COEL, Sphere Fluidics new laboratories are in addition to offices at Babraham Research Campus, also in Cambridgeshire (UK).
For more information about Sphere Fluidics, please visit: https://spherefluidics.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005510/en/

Frost & Sullivan Recognizes Leading Organizations with Prestigious 2022 Best Practices Awards

Retrieved on:

星期一, 八月 1, 2022

SAN ANTONIO, Aug. 1, 2022 /PRNewswire/ -- The best in business assembled in Minneapolis, MN at the 2022 Frost & Sullivan Best Practices Awards Gala held at the Hilton. The gathering honored top business achievements of some of the most innovative and successful companies in their fields.

Key Points:

SAN ANTONIO, Aug. 1, 2022 /PRNewswire/ -- The best in business assembled in Minneapolis, MN at the 2022 Frost & Sullivan Best Practices Awards Gala held at the Hilton.
"Frost & Sullivan presents Best Practices awards to companies that inspire growth in their industries.
They are the game changers," said Jeff Frigstad, Global Sr. Vice President, Best Practices, Frost & Sullivan.
Frost & Sullivan Best Practices awards recognize companies each year in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.